Clinical experience with daptomycin for outpatient parenteral antibiotic therapy

American Journal of the Medical Sciences

Volumn 342, Issue 6, 2011, Pages 486-488

  Larioza, Julius ^a,b   Girard, Amy ^a   Brown, Richard B ^a,b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Daptomycin; Gram positive bacterial infections; Higher doses of treatment; Longer intervals of treatment; Outpatient parenteral antimicrobial therapy

Indexed keywords

CREATINE KINASE; DAPTOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; FEMALE; GRAM POSITIVE INFECTION; HUMAN; KIDNEY INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MONOTHERAPY; ORTHOPEDIC SURGERY; OSTEOMYELITIS; OUTPATIENT; OUTPATIENT CARE; POSTOPERATIVE COMPLICATION; SKIN INFECTION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 82355185960     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31821e1e6b     Document Type: Article

References (14)

1. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004;38:1651-72. (Pubitemid 38781656)
2. Fowler VJ, Boucher H, Corey G, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
3. Cunha BA, Eisenstein L, Hamid NS. Pacemaker-induced Staphylo-coccus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 2006;35:207-11.
4. Cunha BA, Krol V, Kodali V. Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. Heart Lung 2008;37:72-5.
5. Bassetti M, Nicco E, Ginocchio F, et al. High-dose Daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents 2010;36:459-61.
6. Chaftari AM, Hachem R, Mulanovich V, et al. Efficacy and safety of daptomycin in the treatment of gram-positive catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 2010;36: 182-6.
7. Rehm SJ, Campion M, Katz DE, et al. Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. J Anti-microb Chemother 2009;63:1034-42.
8. Martone WJ, Lindfield K, Katz DE. Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Practice 2008;62:1183-7. (Pubitemid 351977621)
9. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38:994-1000. (Pubitemid 38457208)
10. Kanafani ZA, Kourany WM, Fowler VG Jr, et al. Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis. Eur J Clin Microbiol Infect Dis 2009;28: 1477-82.
11. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Disease Society of America, and the Society of Infectious Disease Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
12. Larioza J, Heung L, Brown RB. Management of infective endocarditis in outpatients: clinical experience with outpatient parenteral antibiotic therapy. South Med J. 2009;102:575-9.
13. Sakoulas G, Brown J, Lamp KC, et al. Clinical outcomes for patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the cubicin outcomes registry and experience. Clin Ther 2009;31:1936-45.
14. Figueroa DA, Mangini E, Arnodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:177-83.